Description
Product Details
Femoston 1/5 is a combined oral Hormone Replacement Therapy (HRT) formulation containing estradiol (1 mg) and dydrogesterone (5 mg). It is designed for continuous hormone replacement in postmenopausal women with an intact uterus to relieve estrogen deficiency symptoms and help reduce the risk of postmenopausal osteoporosis when alternative therapies are unsuitable.
Active Ingredients & Mechanism of Action
Estradiol (1 mg): A biologically identical human estrogen that directly replaces declining endogenous estrogen levels in postmenopause.
Dydrogesterone (5 mg): A selective progestogen that protects the endometrium from unopposed estrogen stimulation, minimizing the risk of endometrial hyperplasia.
In combination, estradiol ameliorates vasomotor and genitourinary symptoms, and dydrogesterone provides endometrial protection — a clinical necessity in women with an intact uterus.
Indications
Femoston 1/5 Tablets (84s) are indicated for:
Relief of menopausal symptoms (e.g., hot flushes, night sweats, vaginal dryness) in women ≥ 12 months after last menstrual period.
Prevention of postmenopausal osteoporosis in women at high fracture risk when non-estrogen alternatives are inappropriate.
Posology & Administration
Regimen: Continuous daily dosing — one tablet taken orally once daily at the same time each day.
Administration: Swallow whole; may be taken with or without food.
Scheduling: No tablet-free intervals; once a pack is completed, start the next without interruption.
Missed Dose: If ≤ 12 hours late, take ASAP; if > 12 hours, skip and resume regular schedule. Do not double doses.
Clinical Note: Continuous HRT typically results in bleed-free therapy after initial months in women who are fully postmenopausal. Short-term breakthrough bleeding or spotting can occur early in therapy.
Key Safety & Monitoring Points
Contraindications
Femoston must not be prescribed in women with:
- Known hormone-dependent malignancies (e.g., breast or endometrial cancer).
- Active or recent venous thromboembolism, stroke, or coronary artery disease.
- Undiagnosed vaginal bleeding.
- Liver dysfunction or disease.
- Pregnancy or suspected pregnancy.
Precautions
Before and during treatment, assess for:
- Breast cancer risk factors & periodic breast exams.
- Cardiovascular risk (smoking, diabetes, hypertension).
- History of thromboembolic disorders.
- Liver function abnormalities.
- Migraine or severe headache histories.
Regular follow-up should include blood pressure monitoring and periodic evaluation of symptom control and tolerability.
Adverse Effect Profile
Common reactions (typically transient):
- Headache, breast tenderness, abdominal discomfort, nausea, back pain.
- Breakthrough spotting/bleeding in early months.
Uncommon/serious risks:
- Venous thromboembolism (VTE) and stroke — risk increases with age and smoking.
- Breast and endometrial cancer risk elevations with prolonged HRT use.
- Gallbladder disease, hypertension, mood changes.
- Rare events include meningioma and probable dementia in older women.
Urgent Stop & Assess: Sudden leg swelling/pain, chest pain, dyspnea, jaundice, new severe headache, or unexpected vaginal bleeding.
Drug–Drug Interactions
Estrogen metabolism may be altered by enzyme-inducing agents (e.g., rifampicin, carbamazepine, phenytoin) and herbal inducers such as St John’s Wort; this may reduce HRT efficacy and increase breakthrough bleeding.
Clinical Considerations for Prescribers
- Start with the lowest effective dose and tailor duration to symptom burden and risk profile.
- Continuous regimens like Femoston 1/5 are often preferred in women who want to avoid cyclic withdrawal bleeding.
- Discuss long-term safety with patients, especially regarding breast and cardiovascular risks associated with systemic HRT.
- Ensure comprehensive shared decision-making that includes risk stratification and individualized monitoring plans.
